Polymyxin derivatives that sensitize Gram-negative bacteria to other antibiotics

Molecules

Volumn 24, Issue 2, 2019, Pages

  Vaara, Martti ^a,b  

^a Technopolis   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Acinetobacter baumannii; Clinical phase 1 study; Enterobacteriaceae; NAB7061; Permeabilizers; Polymyxin B nonapeptide (PMBN); Pseudomonas aeruginosa; SPR741 NAB741; Synergism

Indexed keywords

ANTIINFECTIVE AGENT; POLYMYXIN;

ANALOGS AND DERIVATIVES; ANIMAL; BACTERIUM; CHEMISTRY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC);

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CLINICAL TRIALS, PHASE I AS TOPIC; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 85059895888     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules24020249     Document Type: Review

References (116)

1. Ainsworth, G.C.; Brown, A.M.; Brownlee, G. Aerosporin, an antibiotic produced by Bacillus aerosporus Greer. Nature 1947, 160, 263. [CrossRef]
2. Stansly, P.G.; Shepherd, R.G.; White, J. Polymyxin: A new chemotherapeutic agent. Bull. Johns Hopkins Hosp. 1947, 81, 43–54.
3. Benedict, R.G.; Langlykke, A.F. Antibiotic activity of Bacillus polymyxa. J. Bacteriol. 1947, 54, 24–25. [PubMed]
4. van Dellen, T.R. New wonder drug labeled polymyxin. The Spokesman-Review, 16 October 1948.
5. Tumbrarello, M.; Raffaella Losito, A.; Giamarellou, H. Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. Curr. Opin. Infect. Dis. 2018, 31, 536–577.
6. Otter, J.A.; Burgess, P.; Davies, P.; Mookerjee, S.; Singleton, J.; Gilchrist, M.; Parrons, D.; Brannigan, E.T.; Robotham, J.; Holmes, A.H. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae; an economic evaluation from a hospital perspective. Clin. Microbiol. Infect. 2017, 23, 188–196. [CrossRef]
7. Bonomo, R.A.; Burd, E.M.; Conly, J.; Limbago, B.J.; Poirel, L.; Segre, J.A.; Westblade, L.F. Carbapenem-producing organisms: A global scource. Clin. Infect. Dis. 2018, 66, 1290–1297. [CrossRef] [PubMed]
8. Bassetti, M.; Giagobbe, D.R.; Giamarrellou, G.; Viscoli, C.; Daikos, G.L.; Dimopoulos, G.; De Rosa, F.G.; Giamarelles-Bourboulis, E.J.; Rossolini, G.M.; Righi, E.; et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin. Microbiol. Infect. 2018, 24, 133–144. [CrossRef]
9. Doan, T.L.; Fung, F.B.; Mehta, D.; Riska, P.F. Tigecycline: A glycylcycline antimicrobial agent. Clin. Ther. 2006, 28, 1079–1106. [CrossRef]
10. Liu, Y.Y.; Wang, Y.; Walsh, T.R.; Yi, L.X.; Zhang, R.; Spencer, J.; Doi, Y.; Tian, G.; Dong, B.; Huang, X.; et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. Lancet Infect. Dis. 2016, 16, 161. [CrossRef]
11. Baron, S.; Hadjadj, L.; Rolain, J.M.; Olaitan, A.O. Molecular mechanisms of polymyxin resistance: Knowns and unknowns. Int. J. Antimicrob. Agents 2016, 48, 583–591. [CrossRef]
12. Jeannot, K.; Bolard, A.; Plésiat, P. Resistance to polymyxins in Gram-negative organisms. Int. J. Antimicrob. Agents 2017, 49, 526–535. [CrossRef] [PubMed]
13. Poirel, L.; Jayol, A.; Nordmann, P. Polymyxins: Antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin. Microbiol. Rev. 2017, 30, 557–596. [CrossRef] [PubMed]
14. SENTRY: SENTRY antimicrobial surveillance program. Available online: https://sentry-mvp.jmilabs.com/ (accessed on 10 January 2019).
15. Lob, S.; Hackel, M.; Badal, R.; Young, K.; Motyi, M.; Sahm, D. Global Prevalence of Colistin and Carbapenem-Resistant Gram-Negative Organisms: SMART 2015–2016; Poster 375; ID Week 2017: San Diego, CA, USA, 2017.
16. Cassini, A.; Diaz Högberg, L.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Skov Simonsen, G.; Colomb-Catinat, M.; Kretzscham, M.E.; Devleesschauwer, B.; Cecchini, M.; et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2018. [CrossRef]
17. Vaara, M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 1992, 56, 395–401. [PubMed]
18. Vaara, M. Novel derivatives of polymyxins. J. Antimicrob. Chemother. 2013, 68, 1213–1219. [CrossRef] [PubMed]
19. Vaara, M.; Vaara, T.; Jenssen, M.; Helander, I.; Nurminen, M.; Rietchel, E.T.; Mäkelä, P.H. Characterization of the lipopolysaccharide from the polymyxin-resistant pmrA mutants of Salmonella typhimurium. FEBS Lett. 1981, 29, 145–148. [CrossRef]
20. Vaara, M. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin and colistin. Med. Res. Rev. 2018, 38, 1661–1673. [CrossRef]
21. Rabanal, F.; Cajal, Y. Recent advances and perspectives in the design and development of polymyxins. Nat. Prod. Rep. 2017, 34, 886–908. [CrossRef]
22. Brown, P.; Dawson, M.J. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. J. Antibiot. 2017, 70, 386–394. [CrossRef]
23. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: Studies on polymyxin B nonapeptide. Biochemistry 2000, 39, 11838–11844. [CrossRef]
24. Vaara, M.; Vaara, T. Sensitization of Gram-negative bacteria to antibiotics and complement by a non-toxic oligopeptide. Nature 1983, 303, 526–528. [CrossRef] [PubMed]
25. Vaara, M.; Vaara, T. Polycations sensitize enteric bacteria to antibiotics. Antimicrob. Agents Chemother. 1983, 24, 107–113. [CrossRef] [PubMed]
26. Ofek, I.; Cohen, S.; Rahmani, R.; Kabha, K.; Herzig, Y.; Rubinstein, E. Antibacterial Synergism of Polymyxin B Nonapeptide and Hydrophobic Antibiotics in Experimental Gram-Negative Infections in Mice. Antimicrob. Agents Chemother. 1994, 38, 374–377. [CrossRef] [PubMed]
27. Danner, R.L.; Joiner, K.A.; Rubin, M.; Patterson, W.H.; Johnson, M.; Ayers, K.M.; Parrillo, J.E. Purification, Toxicity, and Antiendotoxin Activity of Polymyxin B Nonapeptide. Antimicrob. Agents Chemother. 1989, 33, 1428–1434. [CrossRef] [PubMed]
28. Keirstead, N.D.; Wagoner, M.P.; Bentley, P.; Blais, M.; Brown, C.; Chetham, L.; Ciaccio, P.; Dragan, Y.; Ferguson, D.; Fikes, J.; et al. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol. Sci. 2014, 137, 278–291. [CrossRef] [PubMed]
29. Nilsson, A.; Goodwin, R.J.; Swales, J.G.; Gallagher, R.; Shankaran, H.; Sathe, A.; Pradeepan, S.; Xue, A.; Keirstead, N.; Sakasi, J.C. Investigating nephrotoxicity of polymyxin derivatives by mapping renal distribution using mass spectrometry imaging. Chem. Res. Toxicol. 2015, 28, 823–830. [CrossRef] [PubMed]
30. Coleman, S.; Zabava, T.; Utley, L. Polymyxin B Nonapeptide is Nephrotoxic in Male Cynomolgus monkeys Following 7-Days Repeated Intravenous Dosing. Poster EV0304 22. In Proceedings of the ESCMID 2017, Vienna, Austria, 22–25 April 2017.
31. Oliva, B.; Maiese, W.M.; Greenstein, M.; Borders, D.B.; Chopra, I. Mode of action of the depsipeptide antibiotic LL-AO341 beta 1 and partial characterization of a Staphylococcus aureus mutant resistant to the antibiotic. J. Antimicrob. Chemother. 1993, 32, 817–830. [CrossRef]
32. Ohemeng, K.A.; Podlogar, B.L.; Nguyen, V.N.; Bernstein, J.I.; Krause, H.M.; Hilliard, J.J.; Barrett, J.F. DNA gyrase inhibitory and antimicrobial activities of some diphenic acid monohydroxamides. J. Med. Chem. 1997, 40, 3292–3296. [CrossRef]
33. Nitzan, Y.; Balzam-Sudakevitz, A.; Ashkenazi, A. Eradication of Acinetobacter baumannii by photosensitized agents in vitro. J. Photochem. Photobiol. 1998, 42, 211–218. [CrossRef]
34. Norcia, L.J.; Seibel, S.B.; Kamicker, B.J.; Lemay, M.A.; Lilley, S.C.; Hecker, S.J.; Bergeron, J.M.; Retsema, J.A.; Hayashi, S.F. In vitro microbiological characterization of novel macrolide CP-163,505 for animal health specific use. J. Antibiot. (Tokyo) 1998, 51, 136–144. [CrossRef]
35. Kotani, T.; Nagai, D.; Asahi, K.; Suzuki, H.; Yamao, F.; Kataoka, N.; Yagura, T. Antibacterial properties of some cyclic organobismuth(III) compounds. Antimicrob. Agents Chemother. 2005, 49, 2729–2734. [CrossRef] [PubMed]
36. Baum, E.Z.; Crespo-Carbone, S.M.; Foleno, B.D.; Simon, L.D.; Guillemont, J.; Masietag, M.; Bush, K. MurF inhibitors with antibacterial activity: Effect on muropeptide levels. Antimicrob. Agents Chemother. 2009, 53, 3240–3247. [CrossRef] [PubMed]
37. Matsumoto, Y.; Hayama, K.; Sakakihara, S.; Nishino, K.; Noji, K.; Iino, R.; Yamaguchi, A. Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels. PLoS ONE 2011, 6, e18547. [CrossRef] [PubMed]
38. Guiles, J.W.; Toro, A.; Ochsner, U.A.; Bullard, J.M. Development of 4H-pyridopyrimides: A class of selective bacterial protein synthesis inhibitors. Org. Med. Chem. Lett. 2012, 2, 5. [CrossRef] [PubMed]
39. Duan, F.; Li, X.; Cai, S.; Xin, G.; Wang, Y.; Du, D.; He, S.; Huang, B.; Guo, X.; Zhao, R.; et al. Haloemodin as novel antibacterial agent inhibiting DNA gyrase and bacterial topoisomerase I. J. Med. Chem. 2014, 57, 3707–3714. [CrossRef] [PubMed]
40. Sahlberg Bang, C.; Kinnunen, A.; Karlsson, M.; Önnberg, A.; Söderquist, B.; Persson, K. The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide. BMC Microbiol. 2014, 14, 65. [CrossRef]
41. Pagès, J.-M.; Peslier, S.; Keating, T.A.; Lavigne, J.-P.; Nichols, W.W. Role of the outer membrane and porins in susceptibility of β-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob. Agents Chemother. 2015, 60, 1349–1359. [CrossRef]
42. Jin, J.; Hsieh, Y.-H.; Cui, J.; Damera, K.; Dai, C.; Chaudhary, A.S.; Zhang, H.; Yang, H.; Cao, N.; Jiang, C.; et al. Using chemical probes to assess the feasibility of targeting SecA for developing antimicrobial agents against Gram-negative bacteria. Chem. Med. Chem. 2016, 11, 2511–2521. [CrossRef]
43. Howard, J.J.; Sturge, C.R.; Moustafa, D.A.; Daly, S.M.; Marshall-Batty, K.R.; Felder, C.F.; Zamora, D.; Yabe-Gill, M.; Labandeira-Rey, M.; Bailey, S.M. Inhibition of Pseudomonas aeruginosa by peptide-conjugated phosphodiamidate morpholino oligomers. Antimicrob. Agents Chemother. 2017, 61, e01938. [CrossRef]
44. Kitamura, S.; Owensby, A.; Wall, D.; Wolan, D.W. Lipoprotein signal peptidase inhibitors with antibiotics properties identified trough design of a robust in vitro HT plasform. Cell Chem. Biol. 2018, 25, 301–308. [CrossRef]
45. Gatadi, S.; Gour, J.; Shukla, M.; Kaul, G.; Das, S.; Dasgupta, A.; Malasala, S.; Borra, R.S.; Madhavi, Y.V.; Chopra, S.; et al. Synthesis of 1,2,3-triazole linked 4(3H)-quinazolinones as potent antibacterial agents against multidrug-resistant Staphylococcus aureus. Eur. J. Med. Chem. 2018, 157, 1056–1067. [CrossRef] [PubMed]
46. Feigman, S.; Kim, S.; Pidgeon, S.E.; Yu, Y.; Ongwae, G.M.; Patel, D.S.; Regen, S.; Im, W.; Pires, M.M. Synthetic immunotherapeutics against Gram-negative pathogens. Cell Chem. Biol. 2018, 25, 1185–1194. [CrossRef] [PubMed]
47. Nir, U.; Ladan, H.; Malik, Z.; Nitzan, Y. In vivo effects of porphyrins on bacterial DNA. J. Photochem. Photobiol. B Biol. 1991, 11, 295–306. [CrossRef]
48. Wada, T.; Long, J.C.; Zhang, D.; Vik, S.B. A novel labeling approach supports the five-transmembrane model of subunit α of the Escherichia coli ATP synthase. J. Biol. Chem. 1999, 274, 17353–17357. [CrossRef] [PubMed]
49. Barbosa, M.D.; Lin, S.; Markwalder, J.A.; Mills, J.A.; DeVito, J.A.; Teleha, C.A.; Carlapati, V.; Thompson, A.; Trainor, G.L. Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro. Antimicrob. Agents Chemother. 2002, 46, 3549–3554. [CrossRef] [PubMed]
50. Longbottom, C.J.; Carson, C.F.; Hammer, K.A.; Mee, B.J.; Riley, T.V. Tolerance of Pseudomonas aeruginosa to Melaleuca alternifolia (tea tree) oil is associated with the outer membrane and energy-dependent cellular processes. J. Antimicrob. Chemother. 2004, 54, 386–392. [CrossRef] [PubMed]
51. Champlin, F.R.; Ellison, M.L.; Bullard, J.W.; Conrad, R.S. Effect of outer membrane permeabilization on intrinsic resistance to low triclosan levels in Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 2005, 26, 159–164. [CrossRef]
52. Walther, J.; Bröcker, M.J.; Wätzlich, D.; Nimtz, M.; Rohde, M.; Jahn, D.; Moser, J. Protochlorophyllide: A new photosensitizer for the photodynamic inactivation of Gram-positive and Gram-negative bacteria. FEMS Microbiol. Lett. 2009, 290, 156–163. [CrossRef]
53. Misra, R.; Morrison, K.D.; Cho, H.J.; Khuu, T. Importance of real-time assays to distinguish multidrug efflux pump-inhibiting and outer membrane-destabilizing activities in Escherichia coli. J. Bacteriol. 2015, 197, 2479–2488. [CrossRef]
54. Moison, E.; Xie, R.; Zhang, G.; Lebar, M.D.; Meredith, T.C.; Kahne, D. A fluorescent probe distinguishes between inhibition of early and late steps of lipopolysaccharide biogenesis in whole cells. ACS Chem. Biol. 2017, 12, 928–932. [CrossRef]
55. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Møller, N.; Nagai, J.; Takano, M.; Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 2008, 52, 3229–3236. [CrossRef] [PubMed]
56. Vaara, M.; Siikanen, O.; Apajalahti, J.; Frimodt-Möller, N.; Vaara, T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J. Antimicrob. Chemother. 2010, 65, 942–945. [CrossRef] [PubMed]
57. Vingsbo Lundberg, C.; Vaara, T.; Frimodt-Möller, N.; Vaara, M. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice. J. Antimicrob. Chemother. 2010, 65, 981–985. [CrossRef] [PubMed]
58. Ali, F.E.; Cao, G.; Poydal, A.; Vaara, T.; Nation, R.L.; Vaara, M.; Li, J. Pharmacokinetics of novel antimicrobial cationic peptides NAB7061 and NAB739 in rats following intravenous administration. J Antimicrob. Chemother. 2009, 64, 1067–1070. [CrossRef] [PubMed]
59. Vaara, M.; Vaara, T. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges. Peptides 2010, 31, 2318–2321. [CrossRef] [PubMed]
60. Vaara, M.; Siikanen, O.; Apajalahti, J.; Fox, J.; Frimodt-Møller, N.; He, H.; Poydal, A.; Li, J.; Nation, R.L.; Vaara, T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 2010, 54, 3341–3346. [CrossRef] [PubMed]
61. Spero Therapeutics: Spero Therapeutics announces positive phase 1 clinical data. Available online: https://investors.sperotherapeutics.com/news-releases/news-release-details/spero-therapeutics-announces-positive-phase-1-clinical-data (accessed on 10 January 2019).
62. French, S.; Farha, M.; Rubio, A.; Lister, T.; Cotroneo, N.; Parr, T.R., Jr.; Brown, E.D. Polymyxin Derivative SPR741 Disrupts Gram-Negative Outer Membrane Architecture Without Substantial Impacts on the Cytoplasmic Membrane. Poster Saturday-248. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
63. Murray, B.; Pillar, C.; Pucci, M.; Shinabarger, D. Mechanism of Action of SPR741, a Potentiator Molecule for Gram-Negative Pathogens. Poster Saturday-491. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
64. Anderson, E.M.; Cotroneo, N.; Parr, T.R., Jr.; Lister, T.; Khursigara, C.M. Electron Microscopy Reveals Activity of SPR741 at the Cell Envelope of Escherichia coli. Poster Friday-165. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
65. Anderson, E.M.; Cotroneo, N.; Parr, T.R., Jr.; Lister, T.; Khursigara, C.M. Mechanistic Insight into the Antibiotic Potentiating Activity of SPR741 Using Electron Microscopy. Poster Sunday-222. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
66. Corbett, D.; Wise, A.; Langley, T.; Skinner, E.; Trimby, E.; Birchall, S.; Dorali, A.; Sandford, S.; Williams, J.; Warn, P.; et al. Potentiation of antibiotic activity by a novel cationic peptide: Potency and spectrum of activity of SPR741. Antimicrob. Agents Chemother. 2017, 61, e00200-17. [CrossRef] [PubMed]
67. Veve, M.P.; Wagner, J.L. Lefamulin: Review of a promising novel pleuromutilin antibiotic. Pharmacotherapy 2018, 38, 935–946. [CrossRef]
68. Nabriva: Our goal is to develop new antibiotics. Available online: https://www.nabriva.com/pipeline-research (accessed on 10 January 2019).
69. Hackel, M.; Lister, T.; Parr, T.R., Jr.; Sahm, D. In vitro activity of SPR741 against recent clinical isolates of Escherichia coli and Klebsiella pneumoniae. Poster Saturday-500. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
70. Mendes, R.E.; Rhomberg, P.R.; Becker, H.K.; Davis, A.P.; Lister, T.; Parr, T.R., Jr.; Vaara, M.; Flamm, R.K. Synergistic effect of Gram-positive agents tested in combination with a new polymyxin derivative (SPR741) against multidrug-resistant Gram-negative pathogens. Poster Saturday-490. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
71. Mendes, R.E.; Rhomberg, P.R.; Becker, H.K.; Davis, A.P.; Lister, T.; Lee, A.; Parr, T.R., Jr.; Vaara, M.; Flamm, R.K. Potentiation of clarithromycin when combined with a new cationic peptide against Gram-negative clinical isolates and molecular analysis of macrolide resistance by next-generation sequencing. Poster Sunday-162. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
72. Zurawski, D.Y.; Reinhart, A.A.; Alamneh, Y.A.; Pucci, M.J.; Si, Y.; Abu-Taleb, R.; Shearer, J.P.; Demons, S.T.; Tyner, S.D.; Lister, T. SPR741, an antibiotic adjuvant, potentiates the in vitro and in vivo activity of rifampin against clinically relevant extensively drug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2017, 61, e01239-17. [CrossRef]
73. Hackel, M.; Lister, T.; Parr, T.R., Jr.; Sahm, D. In vitro activity of SPR741 against recent clinical isolates of Acinetobacter baumannii. Poster Saturday-501. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
74. Zou, Y.; Cotroneo, N.; Lister, T.; Rubio, A. Bactericidal activity of piperacillin-tazobactam in combination with SPR741 against susceptible, extended-spectrum beta-lactamase producing, and multidrug resistant Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. Poster P1675. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
75. Mendes, R.E.; Rhomberg, P.R.; Lister, T.; Cotroneo, N.; Rubio, A.; Flamm, R.K. Antimicrobial activity of ceftazidime and piperacillin-tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary tract infections. Poster P1671. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
76. Zou, Y.; Cotroneo, N.; Lister, T.; Rubio, A. Bactericidal activity of ceftazidime in combination with SPR741 against susceptible, extended-spectrum betalactamase-producing, and multidrug resistant Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. Poster P1674. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
77. Mendes, R.E.; Rhomberg, P.R.; Lister, T.; Cotroneo, N.; Rubio, A.; Flamm, R.K. Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of β-lactam agents against a challenge set of Gram-negative pathogens. Poster P1672. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
78. Citron, D.M.; Tyrrell, K.L.; Rubio, A.; Goldstein, E.J. In vitro activity of ceftazidime alone and in combination with SPR741 against anaerobic bacteria. Poster P1673. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
79. Sweeney, D.; Cotroneo, N.; Lister, T.; Rubio, A.; Shinabarger, D.; Pillar, C. The impact of varied test conditions on the in vitro activity of the novel gyrase inhibitor SPR719 in combination with the potentiator SPR741. Poster Saturday-255. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
80. Cotroneo, N.; Zou, Y.; Howells, A.; Parr, T.R., Jr.; Lister, T.; Rubio, A. Activity profile of novel gyrase inhibitors SPR719, SPR750, and SPR751 alone and in combination with potentiator SPR741. Poster Saturday-258. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
81. Mendes, R.E.; Rhomberg, P.R.; Edah, Y.; Lister, T.; Parr, T.R., Jr.; Vaara, M.; Flamm, R.K. Synergistic effect of novel gyrase inhibitor agents (SPR750 and SPR751) in combination with a polymyxin derivative (SPR741) against recent Acinetobacter baumannii and Enterobacteriaceae. Poster Sunday-13. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
82. Hackel, M.; Lister, T.; Parr, T.R., Jr.; Vaara, M.; Sahm, D. In vitro activity of SPR741 combined with three novel compounds against recent clinical isolates of Acinetobacter baumannii and Enterobacteriaceae. Poster Sunday-27. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
83. Mendes, R.E.; Rhomberg, P.R.; Lee, A.; Lister, T.; Parr, T.R., Jr.; Vaara, M.; Flamm, R.K. Antimicrobial synergistic effect of a new anti-Gram-positive agents tested in combination with a polymyxin derivative against Gram-negative pathogens, including ESKAPE group organisms. Poster Sunday-23. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
84. Brunati, C.; Thomsen, T.T.; Gaspari, E.; Maffiolo, S.; Sosio, M.; Jabes, D.; Løbner-Olelen, A.; Donaldo, S. Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: Synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells. J. Antimicrob. Chemother. 2018, 73, 414–424. [CrossRef]
85. Chopra, I.; Hacker, K. Uptake of minocycline by Escherichia coli. J. Antimicrob. Chemother. 1992, 29, 19–25. [CrossRef]
86. Rubio, A.; Weiss, W.J.; Pulse, M.; Lister, T.; Parr, T.R., Jr. In vivo efficacy of combinations of novel antimicrobial peptide SPR741 and rifampin in a K. pneumoniae murine model of urinary tract infection. Poster Saturday-249. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
87. Weiss, W.J.; Pulse, M.; Nguyen, P.; Parr, T.R., Jr.; Lister, T.; Rubio, A. Efficacy of novel cationic peptide SPR741 and gyrase inhibitor SPR720 combinations against carbapenem-resistant K. pneumoniae in a murine UTI model. Poster Saturday-259. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
88. Warn, P.; Sattar, A.; Thommes, P.; Corbett, D.; Holden, K.; Lister, T.; Parr, T.R., Jr. In vivo efficacy of combinations of novel antimicrobial cationic peptide SPR741 and clarithromycin in short-duration murine thigh and lung models of Gram-negative infection. Poster Saturday-498. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
89. Stainton, S.M.; Abdelraouf, K.; Utley, L.; Pucci, M.; Lister, T.; Nicolau, D.P. Assessment of the in vivo activity of SPR741 in combination with azithromycin against multidrug-resistant Enterobacteriaceae isolates in the neutropenic murine thigh infection model. Antimicrob. Agents Chemother. 2018, 62, e00239-18. [CrossRef] [PubMed]
90. Warn, P.; Corbett, D.; Gould, J.; Parker, G.; Daws, G.; Thommes, P.; Lister, T.; Parr, T.R., Jr. Impact of dosing regimens on the in vivo efficacy of combinations of novel antimicrobial cationic peptide SPR741 and rifampicin in murine thigh infection models. Poster Saturday-496. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
91. Warn, P.; Thommes, P.; Vaddi, S.; Corbett, D.; Coles, D.; Vaccaro, L.; Lister, T.; Parr, T.R., Jr. In vivo efficacy of combinations of novel antimicrobial peptide SPR741 and rifampicin in short-duration murine thigh infection models of Gram-negative bacterial infection. Poster Monday-561. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
92. Grosser, L.; Heang, K.; Farrington, K.; Thommes, P.; Teague, J.; Payne, L.; Corbett, D.; Parr, T.R., Jr.; Lister, T.; Rubio, A. In vivo characterization of potentiator compound SPR741 in combination with the novel gyrase inhibitor SPR719 in an acute murine thigh infection model. Poster Saturday-256. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
93. Mingeot-Leclerq, M.P.; Tulkens, P.M.; Denamur, S.; Vaara, T.; Vaara, M. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 2012, 35, 248–252. [CrossRef] [PubMed]
94. Weber, E.J.; Lidberg, K.A.; Wang, L.; Bammler, T.K.; MacDonald, J.W.; Li, M.J.; Redhair, M.; Atkins, W.M.; Tran, C.; Hines, K.M.; et al. Safety assessment of polymyxin antibiotics utilizing a human kidney 3 D microphysiological system. JCI Insight 2018. [CrossRef] [PubMed]
95. Coleman, S.; Bleavins, M.; Lister, T.; Vaara, M.; Parr, T.R., Jr. The assessment of SPR741 for nephrotoxicity in Cynomolgus monkeys and Sprague-Dawley rats. Poster Monday-523. In Proceedings of the ASM Microbe 2016—American Society for Microbiology Conference, Boston, CA, USA, 16–20 June 2016.
96. Coleman, S.; Bleavins, M. A GLP 14-day repeat dose toxicology study of SPR741 in monkeys. Poster Saturday-251. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
97. Utley, L.; Coleman, S. Pharmacokinetics of SPR741 in rats and non-human primates after a one hour intravenous infusion. Poster Saturday-247. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
98. Coleman, S.; Bleavins, M. SPR741 GLP safety pharmacology studies across cardiac, pulmonary and central nervous systems. Poster Saturday-252. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
99. Coleman, S.; Bleavins, M. SPR741 is non-genotoxic in the ICH battery of GLP Ames, chromosomal aberration, in in vivo micronucleus studies. Poster Saturday-253. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
100. Utley, L.; Coleman, S. In vitro ADME properties of SPR741 support progression into clinical development. Poster Saturday-254. In Proceedings of the ASM Microbe 2017—American Society for Microbiology Conference, New Orleans, LA, USA, 1–5 June 2017.
101. Eckburg, P.B.; Farinola, N.; Utley, L.; Walpole, S.; Keutzer, T.; Kopp, E.; Coleman, S.; Tomayko, J. Safety of SPR741, a novel polymyxin potentiator, in healthy adults receiving single- and multiple-dose intravenous administrations. Poster P2206. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
102. Utley, L.; Lister, T.; Coleman, S.; Eckburg, P.B. Determination of the pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SPR741 in healthy volunteers. Poster P2233. In Proceedings of the ECCMID 2018, Madrid, Spain, 21–24 April 2018.
103. Brown, P.; Dawson, M.J.; Simonovic, M.; Boakes, S.; Duperchy, E. Polymyxin Derivatives and Their Use in Different Combination Therapies Together with Different. Antibiotics. Patent Application WO 2014/188178, 26 November 2014.
104. Brown, P.; Dawson, M.J.; Simonovic, M.; Boakes, S.; Duperchy, E.; Stanway, S.J.; Wilson, A.; Moss, S.F. Polymyxin Derivatives and Their Use in Combination Therapies Together with Different. Antibiotics. Patent Application WO 2015/135976, 18 September 2015.
105. Lister, T.; Sharma, R.; Zabawa, T.; Zahler, R. Polymyxin Analogs Useful as Antibiotic. Potentiators. Patent Application WO 2017/189866, 3 November 2017.
106. Lister, T.; Sharma, R.; Zabawa, T.; Zahler, R. Serine Replacement Polymyxin Analogues Useful as Antibiotic. Potentiators. Patent Application WO 2017/189868, 3 November 2017.
107. Rabanal, F.; Grau-Campistany, A.; Vila-Farrés, X.; Gonzales-Linares, J.; Borràs, M.; Vila, J.; Manresa, A.; Cajal, Y. A bioinsprired peptide scaffold with high antibiotic activity and low in vivo toxicity. Sci. Rep. 2015, 5, 10558. [CrossRef] [PubMed]
108. Rudilla, H.; Fusté, E.; Cajal, Y.; Rabanal, F.; Vinuesa, T.; Viñas, M. Synergistic antipseudomonal effects of synthetic peptide AMP38 and carbapenems. Molecules 2016, 21, 1223. [CrossRef] [PubMed]
109. Cochrane, S.A.; Vederas, J.C. Unacylated tridecapeptin A1 acts as an effective sensitizer of Gram-negative bacteria to other antibiotics. Int. J. Antimicrob. Agents 2014, 44, 493–499. [CrossRef]
110. Moon, S.H.; Zhang, X.; Zheng, G.; Meeker, D.G.; Smeltzer, M.S.; Huang, E. Novel linear lipopeptide paenipeptins with potential for eradicating biofilms and sensitizing Gram-negative bacteria to rifampicin and clarithromycin. J. Med. Chem. 2017, 60, 9630–9640. [CrossRef]
111. Vaara, M.; Porro, M. Group of peptides that act synergistically with hydrophobic antibiotics against Gram-negative enteric bacteria. Antimicrob. Agents Chemother. 1996, 40, 1801–1805. [CrossRef]
112. Zabava, T.P.; Pucci, M.J.; Parr, T.R., Jr.; Lister, T. Treatment of Gram-negative bacterial infections by potentiation of antibiotics. Curr. Opin. Microbiol. 2016, 33, 7–12. [CrossRef]
113. Tascini, C.; Tagliaferri, F.; Giani, T.; Leonildi, A.; Flammini, S.; Casini, B.; Lewis, R.; Ferrati, S.; Rossolini, G.M.; Menichetti, F. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2013, 57, 3990–3993. [CrossRef] [PubMed]
114. MacNair, C.R.; Stokes, J.M.; Carfrae, L.A.; Flebig-Comyn, A.A.; Coombes, B.K.; Mulvey, M.R.; Brown, E.D. Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat. Commun. 2018, 9, 458–465. [CrossRef] [PubMed]
115. Brennan-Krohn, T.; Pironti, A.; Kirby, J.E. Synergistic activity of colistin-containing combinations against colistin-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 2018, 62, e00873-18. [CrossRef] [PubMed]
116. Tyrrell, J.M.; Aboklaish, A.F.; Walsh, T.R.; Vaara, T.; Vaara, M. The novel polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii. Peptides 2018. [CrossRef]